{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:43:03Z","timestamp":1792676583860,"version":"4.5.0"},"reference-count":28,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,9,9]]},"DOI":"10.2967\/jnumed.126.272783","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:20:16Z","timestamp":1792675216000},"page":"jnumed.126.272783","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical PET Imaging of Trastuzumab Deruxtecan in Tumors with Heterogeneous HER2 Expression"],"prefix":"10.2967","author":[{"given":"Alex","family":"Benton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayla","family":"Shmuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilia","family":"Gastounioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia M.R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026102206201043000_jnumed.126.272783v1.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"2026102206201043000_jnumed.126.272783v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"2026102206201043000_jnumed.126.272783v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"2026102206201043000_jnumed.126.272783v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2"},{"key":"2026102206201043000_jnumed.126.272783v1.5","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","article-title":"Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06) [abstract]","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026102206201043000_jnumed.126.272783v1.6","doi-asserted-by":"crossref","first-page":"834651","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci."},{"key":"2026102206201043000_jnumed.126.272783v1.7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med."},{"key":"2026102206201043000_jnumed.126.272783v1.8","unstructured":"Allison K Krishnamurti U . Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. College of American Pathologists website. https:\/\/www.cap.org\/wp-content\/uploads\/2026\/07\/Breast.Bmk_1.6.1.0.-REL_CAPCP-1.pdf?download=true. Published June 2025. Accessed July 25, 2026."},{"key":"2026102206201043000_jnumed.126.272783v1.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of Low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA. Oncol."},{"key":"2026102206201043000_jnumed.126.272783v1.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.118612"},{"key":"2026102206201043000_jnumed.126.272783v1.11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-018-4696-z","article-title":"Evaluation of [89Zr]Trastuzumab-PET\/CT in differentiating HER2-positive from HER2-negative breast cancer","volume":"169","author":"Dehdashti","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"2026102206201043000_jnumed.126.272783v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193888"},{"key":"2026102206201043000_jnumed.126.272783v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.12"},{"key":"2026102206201043000_jnumed.126.272783v1.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.060392"},{"key":"2026102206201043000_jnumed.126.272783v1.15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11307-025-02022-3","article-title":"MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-trastuzumab for preclinical cancer imaging","volume":"27","author":"Sim\u00f3","year":"2025","journal-title":"Mol Imaging Biol."},{"key":"2026102206201043000_jnumed.126.272783v1.16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00777"},{"key":"2026102206201043000_jnumed.126.272783v1.17","doi-asserted-by":"crossref","first-page":"17588359231152842","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026102206201043000_jnumed.126.272783v1.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267636"},{"key":"2026102206201043000_jnumed.126.272783v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269227"},{"key":"2026102206201043000_jnumed.126.272783v1.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.172031"},{"key":"2026102206201043000_jnumed.126.272783v1.21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41523-023-00610-6","article-title":"Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)","volume":"10","author":"Mileva","year":"2024","journal-title":"NPJ Breast Cancer."},{"key":"2026102206201043000_jnumed.126.272783v1.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265434"},{"key":"2026102206201043000_jnumed.126.272783v1.23","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/pharmaceutics16070882","article-title":"Zirconium 89 and Copper 64 for ImmunoPET: From antibody bioconjugation and radiolabeling to molecular imaging","volume":"16","author":"Badier","year":"2024","journal-title":"Pharmaceutics."},{"key":"2026102206201043000_jnumed.126.272783v1.24","unstructured":"Fondazione IRCCS Istituto Nazionale dei Tumori. RADIomics to predict HER2 status and T-DXd efficacy in metastatic breast cancer: the RADIOSPHER2 study. ClinicalTrials.gov website. https:\/\/cdn.clinicaltrials.gov\/large-docs\/69\/NCT07030569\/Prot_000.pdf. Published January 23, 2024. Accessed October 5, 2026."},{"key":"2026102206201043000_jnumed.126.272783v1.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2026102206201043000_jnumed.126.272783v1.26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026102206201043000_jnumed.126.272783v1.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905005116"},{"key":"2026102206201043000_jnumed.126.272783v1.28","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:20:18Z","timestamp":1792675218000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":28,"alternative-id":["10.2967\/jnumed.126.272783"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272783","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}